Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company's lead in vitro diagnostic test is Overa, a blood test to aid physicians in pre-surgical assessment of ovarian tumors for malignancy, using an ialgorithmic approach. It serves clinical reference laboratories, hospital laboratories, and physician offices in the United States. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
http://www.priceseries.com/trade/VRML-Vermillion-Inc-stock-gains-51-percent-a-Trade-Record-by-priceSeries-2019030620190325.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments